Loading color scheme

Independent PBM Clients Lower Drug Prices by 37% in First Year

PR Newswire February 11, 2020

The turbulent landscape has fingers pointed in all directions; however, one Pharmacy Benefit Manager (PBM), MC-RX remains diligent is controlling costs and delivering a fresh perspective in otherwise murky waters.

GAINESVILLE, Ga., Feb. 11, 2020 /PRNewswire-PRWeb/ -- Skyrocketing prescription drug prices are enough to make you sick. Just when you thought Big Pharma prices could not get any higher, 471 medications increased an average of 5.1% in the first few days of 2020.

Politicians, lawmakers, and advocates have all stated, "Enough is enough" and vow to prompt legislature to lower drug prices "now." S. 2543, the Prescription Drug Pricing Reduction Act of 2019 (PDPRA), is a bill that proposes reductions in Medicare reinsurance payments from 80% to 20% over a three-year period. This does, however, increase insurers' shares of cost responsibility from 15% to 60%. So, what are the actual savings?

Read more
The Black Box of Drug Pricing has Been Opened; PBM MC-Rx Urges Accountability

Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. More states will follow. These laws represent an important first step in shining a light on why drug prices are rapidly rising. MC-Rx, a PBM advocating for change, argues the need not just for transparency, but accountability in the often secretive flow of funds from the pharmaceutical manufacturer to the ultimate consumer.

Read more
MC-Rx Urges Industry Accountability for PBMs with JoTo PR

Drug prices are a heated topic in American society and in the Federal government. Pharmacy Benefit Managers (PBMs) usually take the blame for rising drug costs with rebate practices. MC-Rx, a full-service PBM, is urging others in the industry to be held accountable for their rebate practices.

Read more